Evidence map›Paper›PMID 40638018›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study.

Takaomi Hagi, Yukinori Kurokawa, Takeshi Omori, Yusuke Akamaru, Keijiro Sugimura, Masaaki Motoori, Jin Matsuyama, Takuro Saito, Kazuyoshi Yamamoto, Tsuyoshi Takahashi and 3 more

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Response to comments on: intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Takaomi Hagi *Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Yukinori Kurokawa *Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan. ykurokawa@gesurg.med.osaka-u.ac.jp.
Takeshi OmoriDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Yusuke AkamaruDepartment of Surgery, Osaka Rosai Hospital, Osaka, Japan.
Keijiro SugimuraDepartment of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
Masaaki MotooriDepartment of Surgery, Osaka General Medical Center, Osaka, Japan.
Jin MatsuyamaDepartment of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan.
Takuro SaitoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Kazuyoshi YamamotoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Tsuyoshi TakahashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExcessive surgical stress induces inflammatory cytokine release, negatively impacting prognosis in patients with malignancies. This study aimed to determine whether the anti-inflammatory effect of a corticosteroid (CS) would improve prognosis when administered intraoperatively to patients with resectable gastric cancer.

methodsIn this multicenter, randomized, open-label, phase II/III study, patients with cStage II-III gastric cancer were randomized to CS administration or non-administration (control) groups. Patients in the CS group received 5 mg/kg of methylprednisolone just before the skin incision during surgery. The primary endpoints were the highest postoperative serum level of C-reactive protein (CRP

resultsBetween December 2016 and February 2019, 410 patients were enrolled. In the phase II portion, CRP

conclusionsIntraoperative CS administration mitigated postoperative CRP elevation but did not result in significantly improved survival in patients with cStage II-III gastric cancer. The study is registered with UMIN-CTR, number UMIN000024465.

Indexed as

Adrenal Cortex HormonesIntraoperative CareMethylprednisoloneStomach NeoplasmsAdultAgedC-Reactive ProteinFemaleGastrectomyHumansMaleMiddle AgedPrognosisSurvival RateAdrenal Cortex HormonesC-Reactive ProteinMethylprednisoloneCorticosteroidC-reactive proteinGastric cancerInflammation

Identifiers

PMID40638018
PMCPMC12378285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.